ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) Director Elisha Finney sold 65 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $179.00, for a total transaction of $11,635.00. Following the completion of the transaction, the director owned 4,871 shares of the company’s stock, valued at approximately $871,909. This trade represents a 1.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
ICU Medical Trading Up 1.1%
Shares of ICUI stock traded up $1.97 during trading hours on Friday, hitting $179.27. 195,454 shares of the company’s stock traded hands, compared to its average volume of 278,884. The stock’s 50 day simple moving average is $163.72 and its 200 day simple moving average is $149.91. The stock has a market cap of $4.48 billion, a PE ratio of 75.01, a price-to-earnings-growth ratio of 2.23 and a beta of 0.88. ICU Medical, Inc. has a 12 month low of $113.37 and a 12 month high of $192.85. The company has a quick ratio of 1.19, a current ratio of 2.37 and a debt-to-equity ratio of 0.52.
ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.30. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. The company had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. During the same quarter in the previous year, the business earned $2.03 earnings per share. ICU Medical’s revenue was up 4.4% compared to the same quarter last year. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current year.
Hedge Funds Weigh In On ICU Medical
Analyst Ratings Changes
Several research analysts have commented on ICUI shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th. KeyCorp increased their price target on ICU Medical from $187.00 to $189.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Piper Sandler lifted their price objective on ICU Medical from $195.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Finally, BTIG Research lifted their price objective on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $195.20.
View Our Latest Analysis on ICUI
ICU Medical Company Profile
ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.
Recommended Stories
- Five stocks we like better than ICU Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
